Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus
January 23, 2025 07:30 ET
|
Attovia Therapeutics, Inc.
ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug...
Ulcerative Colitis Clinical Landscape Report 2021: Pipeline Holds Multiple Novel Prospects in Terms of Distinct Mechanisms of Action and Biologics
July 12, 2021 05:33 ET
|
Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Ulcerative Colitis" report has been added to ResearchAndMarkets.com's offering. UC typically presents with bloody diarrhea, which may...